Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 135Carcinoma, Hepatocellular 81Neoplasms 53Small Cell Lung Carcinoma 51Breast Neoplasms 50Lung Neoplasms 45Triple Negative Breast Neoplasms 41Colorectal Neoplasms 39Melanoma 38Carcinoma, Transitional Cell 37Urinary Bladder Neoplasms 33Neoplasm Metastasis 32Carcinoma, Renal Cell 30Ovarian Neoplasms 20Uterine Cervical Neoplasms 19Stomach Neoplasms 17Squamous Cell Carcinoma of Head and Neck 17Head and Neck Neoplasms 15Liver Neoplasms 14Prostatic Neoplasms 13Glioblastoma 12Solid Tumors 11Recurrence 11Sarcoma 10Esophageal Neoplasms 10Pancreatic Neoplasms 9Lymphoma 9Kidney Neoplasms 9Endometrial Neoplasms 9Mesothelioma, Malignant 8

Interventions

pembrolizumab 1omega-N-Methylarginine 1dehydroftorafur 1atezolizumab 1Specimen Handling 1Restraint, Physical 1Oxaliplatin 1Magnetic Resonance Spectroscopy 1Leucovorin 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
DNA Repair-Deficiency Disorders × atezolizumab × Clear all
NCT02912559 2026-06-01

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

National Cancer Institute (NCI)

Phase 3 Active not recruiting
712 enrolled 14 charts
Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, DNA Repair-Deficiency Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡